Evidence map›Paper›PMID 25275310›Full record

ArticlePLoS genetics2014

Genome-wide discovery of drug-dependent human liver regulatory elements.

Robin P Smith, Walter L Eckalbar, Kari M Morrissey, Marcelo R Luizon, Thomas J Hoffmann, Xuefeng Sun, Stacy L Jones, Shelley Force Aldred, Anuradha Ramamoorthy, Zeruesenay Desta and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Mechanisms and Therapeutic Advances of PXR in Metabolic Diseases and Cancer.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Pregnane X Receptor and the Gut-Liver Axis: A Recent Update.Drug metabolism and disposition: the biological fate of chemicals · 2022
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Robin P SmithDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States of America; Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America.
Walter L EckalbarDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States of America; Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America.
Kari M MorrisseyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States of America.
Marcelo R LuizonDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States of America; Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America.
Thomas J HoffmannInstitute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.
Xuefeng SunDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States of America; Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America.
Stacy L JonesDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States of America; Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America.
Shelley Force AldredSwitchGear Genomics, Menlo Park, California, United States of America.
Anuradha RamamoorthyDepartment of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Zeruesenay DestaDepartment of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Yunlong LiuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Todd C SkaarDepartment of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Nathan D TrinkleinSwitchGear Genomics, Menlo Park, California, United States of America.
Kathleen M GiacominiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States of America; Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America.
Nadav AhituvDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States of America; Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America.
University of California, San Francisco · USIndiana University School of Medicine

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
PHARMACOGENETICS OF MEMBRANE TRANSPORTERSU01GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2000 to 2009
$29.2M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Pharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YEE, SOOK WAH · 2010 to 2014
$16.3M
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
Regulation of drug metabolizing enzymes by miRNAsR01GM088076 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI SKAAR, TODD C. · 2009 to 2017
$3.8M
Characterization of regulatory elements leading to human limb malformationsR01HD059862 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, BEJERANO, GILL · 2009 to 2013
$2.2M
Massively parallel, in vivo functional testing of regulatory elementsR01HG006768 · NHGRI · UNIVERSITY OF WASHINGTON · PI AHITUV, NADAV, SHENDURE, JAY ASHOK · 2012 to 2014
$1.8M
Computational & Functional Annotation of the Zebrafish Genome Regulatory ToolboxR01HG005058 · NHGRI · STANFORD UNIVERSITY · PI AHITUV, NADAV, BEJERANO, GILL · 2009 to 2012
$1.6M
Identification & functional characterization of SIM1 obesity-associated variantsR01DK090382 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, VAISSE, CHRISTIAN · 2012 to 2015
$1.3M
Characterization of neuronal gene regulatory elements associated with epilepsyR01NS079231 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV · 2012 to 2015
$1.2M
NCATS NIH HHS UL1 TR001108NHGRI NIH HHS R01 HG005058NHGRI NIH HHS R01HG005058NHGRI NIH HHS R01 HG006768NHGRI NIH HHS R01HG006768NICHD NIH HHS R01 HD059862NICHD NIH HHS R01HD059862NIDDK NIH HHS 1R01DK090382NIDDK NIH HHS P30 DK026743NIDDK NIH HHS R01 DK090382NIGMS NIH HHS GM61390NIGMS NIH HHS R01 GM088076NIGMS NIH HHS T32 GM007175NIGMS NIH HHS U01 GM061390NIGMS NIH HHS U19 GM061390NINDS NIH HHS 1R01NS079231NINDS NIH HHS R01 NS079231
6 · The paper itself

Abstract

Inter-individual variation in gene regulatory elements is hypothesized to play a causative role in adverse drug reactions and reduced drug activity. However, relatively little is known about the location and function of drug-dependent elements. To uncover drug-associated elements in a genome-wide manner, we performed RNA-seq and ChIP-seq using antibodies against the pregnane X receptor (PXR) and three active regulatory marks (p300, H3K4me1, H3K27ac) on primary human hepatocytes treated with rifampin or vehicle control. Rifampin and PXR were chosen since they are part of the CYP3A4 pathway, which is known to account for the metabolism of more than 50% of all prescribed drugs. We selected 227 proximal promoters for genes with rifampin-dependent expression or nearby PXR/p300 occupancy sites and assayed their ability to induce luciferase in rifampin-treated HepG2 cells, finding only 10 (4.4%) that exhibited drug-dependent activity. As this result suggested a role for distal enhancer modules, we searched more broadly to identify 1,297 genomic regions bearing a conditional PXR occupancy as well as all three active regulatory marks. These regions are enriched near genes that function in the metabolism of xenobiotics, specifically members of the cytochrome P450 family. We performed enhancer assays in rifampin-treated HepG2 cells for 42 of these sequences as well as 7 sequences that overlap linkage-disequilibrium blocks defined by lead SNPs from pharmacogenomic GWAS studies, revealing 15/42 and 4/7 to be functional enhancers, respectively. A common African haplotype in one of these enhancers in the GSTA locus was found to exhibit potential rifampin hypersensitivity. Combined, our results further suggest that enhancers are the predominant targets of rifampin-induced PXR activation, provide a genome-wide catalog of PXR targets and serve as a model for the identification of drug-responsive regulatory elements.

Indexed as

Regulatory Sequences, Nucleic AcidCells, CulturedCytochrome P-450 CYP3AGene Expression RegulationGenome, HumanHepatocytesHep G2 CellsHistonesHumansLiverp300-CBP-Associated Factorp300-CBP Transcription FactorsPolymorphism, Single NucleotidePregnane X ReceptorPromoter Regions, GeneticReceptors, SteroidCYP3A4 protein, humanCytochrome P-450 CYP3AHistonesp300-CBP-Associated Factorp300-CBP Transcription FactorsPregnane X ReceptorReceptors, SteroidRifampin

Identifiers

PMID25275310
PMCPMC4183418
OpenAlexW2087192577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.